a b s t r a c t
In addition to its high affinity for antibody Fc domains, staphylococcal Protein A has been shown to bind certain Fab domains. We investigated this in order to develop a small, recombinant Protein A-binding alternative to immunoglobulin G (IgG) from nanobodies, single-domain antibodies derived from a camelid variant IgG's variable region. We engineered a nanobody with affinity solely for Protein A as well as a dimerized version of higher affinity for typical multidomain Protein A constructs. Because this recombinant nanobody can be immobilized using a cleavable crosslinker, it has proven to be suitable for the isolation and mild elution of protein complexes in native conditions. Ó 2015 Elsevier Inc. All rights reserved.
Staphylococcal Protein A (PrA) 1 and its derivatives continue to be widely used biological tools due to their high affinity for the Fc domain of many antibodies. It is a commonly used protein tag, with multiple copies of its five homologous antibody-binding domains often used to increase overall avidity to immunoglobulin G (IgG) binding partners. Curiously, in addition to its well-known affinity for the Fc region, PrA has been found to bind certain immunoglobulins through their Fab domains using a distinct binding mechanism [1, 2] . It has similarly been observed that recombinant nanobodies, which are derived from camelid heavy chain-only V H H antibody variants, can sometimes bind PrA through their Fab-like single-variable domain [3] . In their typical role as antigen-binding proteins, nanobodies have proven to be valuable reagents in various proteomic and cell biological applications [4] [5] [6] . These small recombinant proteins can bind antigens with high affinity, and their versatility and ease of production have made them a valuable and accessible tool for many investigators [7] . To date, standard purified IgG protein has been the reagent of choice for isolating PrA-tagged complexes [8, 9] , recently supplemented by an engineered high-affinity affibody [10] . However, the heterogeneous nature of IgG preparations, high molecular weight, lot-to-lot variation, and cost make these less than ideal for many applications, particularly in proteomics. In addition, we have found that any particular recombinant protein used for affinity binding of a single target can display unpredictable off-target binding in certain systems, making it valuable to have more than one available option [11] . Given the well-established ease of use and versatility of nanobodies, we sought to generate such a reagent with high affinity for PrA.
In the course of generating nanobody repertoires against various antigens, we observed that approximately half of identified nanobody clones bound robustly to PrA, consistent with previous studies [3, 11] . Sequence alignments of PrA binders revealed highly conserved framework regions. These sequences all contained CDR (complementarity-determining region) loops specific for their original antigen, however, and to generate a nanobody with no extraneous binding activity, we synthesized four sequence variants derived from these consensus sequences with minimal or absent CDR loops (Fig. 1A) . Once synthesized and expressed in Escherichia coli with a periplasmic leader sequence, all four proteins (termed llama antibody against Protein A, or LaP-1 to LaP-4) showed high levels of overexpression and high solubility after periplasmic purification. These crude periplasm preparations were incubated with PrA-Sepharose, and all constructs displayed high affinity, particular LaP-1, which was selected for follow-up studies (see Supplementary  Fig. 1A in online supplementary material). In all cases, no detectable binding was observed for the original antigen (data not shown).
Surface plasmon resonance (SPR) analysis was performed to determine the binding kinetics of LaP-1's interactions with multiple recombinant PrA constructs containing 1, 2, or 4 repeats of the IgG-binding domain ( applications, it was reasoned that this affinity could be increased by generating a homodimeric form of the nanobody. Two copies of the LaP-1 sequence, therefore, were fused using a glycine-rich peptide linker (3 repeats of GGGGS). Because the LaP-1 monomer is only 13 kDa, even this dimerized form remains a relatively small 27 kDa. After purification, the PrA affinities of this 2ÂLaP-1 fusion protein were similarly assessed by SPR (Fig. 1B and C and Supplementary Fig. 2 ). When binding to 2ÂPrA or 4ÂPrA constructs, the affinity of the dimer was more than 300-fold stronger than the LaP-1 monomer, with a K D of 360 to 370 pM. -1, 2ÂLaP-1 , or rabbit IgG was conjugated to epoxy-activated magnetic beads and used to isolate E. coli RpoC-PrA (an RNA polymerase subunit) as well as S. cerevisiae Nup84-PrA (an NPC subcomplex component) and Cdc33-PrA (a protein in the mRNA cytoplasmic cap-binding complex). Bands previously determined by mass spectrometry are labeled. (B) LaP-1 was reversibly immobilized to magnetic beads using SPDP crosslinker and used for affinity isolations as in panel A. Bound protein was first eluted in 25 mM DTT before release of remaining bound protein in lithium dodecyl sulfate (LDS). The yield of protein recovered in the DTT elution step, as compared with total eluted protein, is listed with the standard error. All experiments were performed in duplicate.
Given the structural similarity of the nanobody variable region to other mammalian Fab fragments, it was hypothesized that the LaP-1 nanobodies interacted with PrA through an analogous binding surface rather than an Fc-like binding mechanism [1, 12] . To test this, mutagenesis was done across the homologous sequences corresponding to this binding region (Fig. 1D) [13] . Mutations in two residues, R21 and N85, eliminated PrA binding. These are both present in the homologous binding region and are expected to be necessary for PrA binding via a Fab-like interaction. A model of the proposed PrA/ LaP-1 interaction was also generated via homology to a PrA/Fab crystal structure (PDB ID: 1DEE) [13] using the program I-TASSER [14] [15] [16] and is consistent with the mutagenesis results (Fig. 1E) .
To investigate the specificity and versatility of these anti-PrA nanobodies, we assessed their effectiveness in ex vivo affinity isolations of PrA-tagged protein complexes from yeast and bacteria. LaP-1 and 2ÂLaP-1 proteins were conjugated to magnetic beads and used to isolate tagged RNA polymerase from E. coli [17] , the Saccharomyces cerevisiae Nup84 subcomplex of the nuclear pore complex (NPC) [18, 19] , and messenger RNA (mRNA) cytoplasmic cap-binding complex [20] (Fig. 2A) . In all cases, both the monomeric and dimeric LaP-1 proteins were able to efficiently isolate the targeted complex with yield and purity comparable to control affinity isolations with polyclonal IgG and negligible nonspecific binding or contamination. The tandem affinity purification (TAP) tag is a frequently used PrA alternative, containing two artificial PrA Z domains [21] . However, consistent with other studies showing weak binding between this Z domain and Fab fragments [1, 22] , our LaP-1 proteins are able to recover only very limited amounts of TAP-tagged protein in affinity isolations (Supplementary Fig. 1B) . The PrA Z domains in the TAP tag have only a single glycine-to-alanine point mutation, however, so binding should be restored by reverting this mutation.
In addition to these original LaP-1 proteins, we generated constructs containing an additional free cysteine at the C terminus. Thus, thiol chemistry can be targeted to the C terminus, which allowed us to reversibly immobilize LaP-1 to magnetic aminecoated Dynabeads using an N-succinimidyl 3-(2-pyridyldithio)-propionate (SPDP) crosslinker with a 12-unit PEG (polyethylene glycol) spacer. This produces a disulfide-containing crosslink to the bead, which is easily cleavable in mild reducing conditions [23, 24] . Beads with LaP-1 immobilized in this manner were tested in isolations of RNA polymerase, Nup84, and Cdc33 as before. Again, yield and purity comparable to IgG were observed, and by a short incubation with 25 mM dithiothreitol (DTT), 42 to 86% of the isolated protein could be eluted (Fig. 2B ). This level of elution efficiency is comparable to that seen in other native methods of PrA release [21, 25] . The complex-to-complex difference in yield is also a consistent phenomenon, likely due to differences in interactions with the bead surface. This approach does necessarily lead to release of both PrA-associated and -unassociated LaP-1 nanobody in the elution. Due to the small size (13 kDa) of LaP-1, however, an additional purification step such as gradient centrifugation, which is often necessary for sensitive downstream applications (e.g., electron microscopy), can easily remove unbound nanobody.
In either monomeric or dimeric form, the LaP-1 nanobody is suitable for highly efficient isolation of PrA-tagged protein targets. As a small recombinant protein, it is an especially flexible reagent, as shown in its use in native elutions of protein complexes, making it a convenient option for any application making use of a PrAbased tag.
